ArticleInternational journal of general medicine2026
Predictive Value of First-Trimester Serum TREM2 and SIGLEC1 Levels for Adverse Pregnancy Outcomes in Women with PCOS.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the predictive value of first-trimester serum triggering receptor expressed on myeloid cells 2 (TREM2) and sialic acid-binding immunoglobulin-like lectin 1 (SIGLEC1) levels for adverse pregnancy outcome (APO) in pregnant women with polycystic ovary syndrome (PCOS), and to provide novel biomarkers for risk stratification management during pregnancy. Methods: This retrospective cohort study enrolled 380 singleton pregnant women with PCOS diagnosed between August 25, 2022, and January 25, 2025. Serum samples collected at gestational weeks 6-12 were retrieved from the biobank. TREM2 and SIGLEC1 concentrations were measured using ELISA. Participants were stratified into APO (n=117) and non-APO (n=263) groups. Receiver operating characteristic (ROC) curve analysis assessed predictive performance, and multivariable logistic regression identified independent risk factors. Results: Comparison of clinical data revealed that serum TREM2 and SIGLEC1 levels in the first trimester were significantly higher in the APO group than in the non-APO group (p < 0.05). Additionally, waist circumference, fasting plasma glucose (FPG), fasting insulin (FINS), and homeostatic model assessment for insulin resistance (HOMA-IR) were all significantly elevated in the APO group compared with the non-APO group (all p < 0.001). ROC analysis showed TREM2 achieved an area under the curve (AUC) of 0.828 (sensitivity 80.23%, specificity 75.21%) and SIGLEC1 yielded an AUC of 0.815 (sensitivity 83.65%, specificity 63.25%). The combined model demonstrated superior predictive accuracy (AUC 0.899, sensitivity 84.79%, specificity 82.05%). Multivariable logistic regression analysis demonstrated that elevated waist circumference (OR = 1.035, 95% CI: 1.010-1.060), HOMA-IR (OR = 2.027, 95% CI: 1.053-3.902), TREM2 (OR = 1.007, 95% CI: 1.005-1.009), and SIGLEC1 (OR = 1.006, 95% CI: 1.004-1.008) were all independent risk factors for APO in pregnant women with PCOS (all p < 0.05). TREM2 and SIGLEC1 levels positively correlated with HOMA-IR (r=0.202 and 0.231, respectively; both p < 0.001). Conclusion: Elevated serum TREM2 and SIGLEC1 levels in early pregnancy are associated with overall APO risk in PCOS patients, and their combined detection shows predictive potential; differential predictive values for specific outcome subtypes await further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.